4
Changes in Ownership
CytomX Therapeutics, Inc. Filed Acc 0001140361-18-035277
Chief Financial Officer sold 3,000 shares at $26.05 ($78,150)
- Chief Financial Officer acquired 3,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
RAY DEBANJAN · Chief Financial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2018-08-01 | Exercise or conversion : show line 1 in the form | +2,710 | $1.26 | $3,414 | 8,638 | D |
| 2018-08-01 | Exercise or conversion : show line 2 in the form | +290 | $1.45 | $420 | 8,928 | D |
| 2018-08-01 | Sale : show line 3 in the form | −3,000 | $26.05 | $78,150 | 5,928 | D |
| Open-market sales · 3,000 sh · avg $26.05 · $78,150 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2018-08-01 | Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) | +2,710 | 0 | D |
| 2018-08-01 | Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) | +290 | 19,220 | D |
Loading xslF345X03/doc1.xml…